Lightpath Technologies Inc (LPTH) investors sentiment increased to 2 in 2018 Q1. It’s up 0.36, from 1.64 in 2017Q4. The ratio increased, as 14 institutional investors started new or increased equity positions, while 7 decreased and sold equity positions in Lightpath Technologies Inc. The institutional investors in our database now hold: 7.12 million shares, up from 6.98 million shares in 2017Q4. Also, the number of institutional investors holding Lightpath Technologies Inc in top ten equity positions was flat from 0 to 0 for the same number . Sold All: 3 Reduced: 4 Increased: 8 New Position: 6.
The stock of Synlogic, Inc. (NASDAQ:SYBX) is a huge mover today! The stock decreased 2.99% or $0.29 during the last trading session, reaching $9.42. About 74,586 shares traded. Synlogic, Inc. (NASDAQ:SYBX) has declined 8.12% since June 13, 2017 and is downtrending. It has underperformed by 20.69% the S&P500. Some Historical SYBX News: ; 05/03/2018 Synlogic to Webcast Presentation at the Cowen and Company 38th Annual Health Care Conference; 25/04/2018 – SYNLOGIC INC – PHASE 1/2A CLINICAL STUDY OF SYNB1618 EXPECTED TO REPORT INTERIM DATA IN 2018; 06/04/2018 – SYNLOGIC INC – ALSO INTENDS TO USE NET PROCEEDS FROM OFFERING TO FUND ITS PLANNED PHASE 1/2A CLINICAL TRIAL OF SYNB1618 THROUGH COMPLETION; 16/04/2018 – HAWKES BAY MASTER INVESTORS (CAYMAN) L.P. REPORTS 5.30 PCT PASSIVE STAKE IN SYNLOGIC INC AS OF APRIL 06, 2018 – SEC FILING; 25/04/2018 – Synlogic Gets FDA Fast-Track Designation for SYNB1618 Synthetic Biotic Medicine for Treatment of Phenylketonuria; 20/03/2018 – SYNLOGIC INC – AS OF DEC 31, 2017, SYNLOGIC HAD CASH, CASH EQUIVALENTS, AND SHORT-TERM INVESTMENTS OF $87.0 MILLION; 12/03/2018 – Synlogic: Expanded Clinical Data Set From Phase 1 Study Confirms Proof of Mechanism and Supports Continued Development of SYNB1020 for Treatment of Hyperammonemia; 15/05/2018 – SYNLOGIC INC – AS OF MARCH 31, 2018, SYNLOGIC HAD CASH, CASH EQUIVALENTS, AND SHORT-TERM INVESTMENTS OF $125.8 MLN; 10/05/2018 – Franklin Advisers Inc. Exits Position in Synlogic; 18/04/2018 – SYNLOGIC DOSES FIRST SUBJECT IN PHASE 1/2A TRIAL OF SYNB1618 FOR TREATMENT OF PHENYLKETONURIAThe move comes after 9 months negative chart setup for the $239.75 million company. It was reported on Jun, 13 by Barchart.com. We have $9.14 PT which if reached, will make NASDAQ:SYBX worth $7.19 million less.
LightPath Technologies, Inc. designs, develops, makes, and distributes optical components and assemblies. The company has market cap of $55.45 million. The firm offers precision molded glass aspheric optics, molded and diamond-turned infrared aspheric lenses, GRADIUM glass lenses, and other optical materials used to produce products that manipulate light. It has a 6.93 P/E ratio. The Company’s products are used in various industries, including defense products, medical devices, laser aided industrial tools, automotive safety applications, barcode scanners, optical data storage, hybrid fiber coax datacom, telecommunications, machine vision and sensors, and other industries.
More news for LightPath Technologies, Inc. (NASDAQ:LPTH) were recently published by: Seekingalpha.com, which released: “LightPath Tech Focuses On Autonomous Vehicles” on May 25, 2018. Streetinsider.com‘s article titled: “Roth Capital Remains Bullish on Lightpath Technologies (LPTH) Following Mixed 3Q” and published on May 15, 2018 is yet another important article.
Analysts await LightPath Technologies, Inc. (NASDAQ:LPTH) to report earnings on September, 13. They expect $0.02 EPS, down 91.67% or $0.22 from last year’s $0.24 per share. LPTH’s profit will be $514,626 for 26.94 P/E if the $0.02 EPS becomes a reality. After $0.04 actual EPS reported by LightPath Technologies, Inc. for the previous quarter, Wall Street now forecasts -50.00% negative EPS growth.
Manatuck Hill Partners Llc holds 1.22% of its portfolio in LightPath Technologies, Inc. for 1.05 million shares. Thompson Davis & Co. Inc. owns 132,260 shares or 0.77% of their US portfolio. Moreover, Penbrook Management Llc has 0.16% invested in the company for 71,800 shares. The British Columbia – Canada-based Vertex One Asset Management Inc. has invested 0.15% in the stock. First Interstate Bank, a Montana-based fund reported 19,000 shares.
The stock decreased 0.69% or $0.015 during the last trading session, reaching $2.155. About 95,966 shares traded. LightPath Technologies, Inc. (LPTH) has declined 33.97% since June 13, 2017 and is downtrending. It has underperformed by 46.54% the S&P500. Some Historical LPTH News: ; 19/04/2018 DJ LightPath Technologies Inc Class , Inst Holders, 1Q 2018 (LPTH)
Ratings analysis reveals 100% of LightPath’s analysts are positive. Out of 2 Wall Street analysts rating LightPath, 2 give it “Buy”, 0 “Sell” rating, while 0 recommend “Hold”. The lowest target is $2.5 while the high is $2.5. The stock’s average target of $2.50 is 16.01% above today’s ($2.155) share price. LPTH was included in 2 notes of analysts from December 22, 2016. The rating was initiated by Roth Capital on Thursday, December 22 with “Buy”. Dougherty & Company initiated LightPath Technologies, Inc. (NASDAQ:LPTH) on Tuesday, January 10 with “Buy” rating.
Another recent and important Synlogic, Inc. (NASDAQ:SYBX) news was published by Streetinsider.com which published an article titled: “Synlogic (SYBX) Highlights New Preclinical Data from Ongoing Phase 1b/2a Clinical Trial Evaluating SYNB1020” on June 04, 2018.
Analysts await Synlogic, Inc. (NASDAQ:SYBX) to report earnings on August, 3. They expect $-0.53 EPS, up 83.17% or $2.62 from last year’s $-3.15 per share. After $-0.55 actual EPS reported by Synlogic, Inc. for the previous quarter, Wall Street now forecasts -3.64% EPS growth.
Synlogic, Inc. develops synthetic biotic medicines for the treatment of patients with urea cycle disorder and phenylketonuria. The company has market cap of $239.75 million.